The ethical incentive program - Don’t let aggressive growth targets drive questionable sales tactics
The ethical incentive program - Don’t let aggressive growth targets drive questionable sales tactics
Insight

The ethical incentive program

Don’t let aggressive growth targets drive questionable sales tactics

As the financial sector reels from government investigations in to incentive programs, a growing number of life sciences board members are asking whether they, too, could be missing critical risks related to their organizations’’ incentive programs. The answer may be yes.

Read more to find out the tough questions life sciences boards should be asking about their incentive programs.

The ethical incentive program -
Don’t let aggressive growth targets drive questionable sales tactics

Related content


KPMG Healthcare & Life Sciences Institute

Register to receive timely insights